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Abstract Raised blood pressure is the leading attributable
risk factor for global morbidity and mortality. Real world data
demonstrates that half of treated patients are at elevated car-
diovascular risk because of inadequately controlled BP. In
addition to pharmacotherapy, certain interventional strategies
to reduce blood pressure and cardiovascular risk in hyperten-
sion can be considered according to international guidelines.
One of the newer technologies entering this field is a propri-
etary arteriovenous coupler device that forms a fixed flow
arteriovenous conduit in the central vasculature. In this review,
we examine the development of and rationale for the creation
of a central arteriovenous anastomosis in patients with hyper-
tension and review the proposed mechanisms by which it may
ameliorate hypertension. We critically review the clinical trial
evidence base to date and postulate on future therapeutic
directions.
Keywords Hypertension . Arterial stiffness . Arteriovenous
anastomosis . Arteriovenous fistula . Interventional devices .
Coupler
Introduction
Raised blood pressure (BP) remains the leading attributable
risk factor for mortality worldwide [1], despite an enormous
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evidence base [2] for the myriad of licensed classes of anti-
hypertensive medications. Only half of treated hypertensive
patients achieve controlled BP to international guideline-
based targets [3, 4]. Furthermore, in patients with
(pharmacologically) resistant hypertension (RHTN, taking
≥3 anti-hypertensive medication classes, including a diuretic
at maximally tolerated doses [5–7]) who remain at excessive
cardiovascular (CV) risk [8], there is a paucity of high-quality,
endpoint-driven evidence to suggest that addition of a fourth
medication (or more) is likely to control BP and reduce excess
morbidity and mortality. Thus, novel therapeutic strategies,
including non-medication approaches, are of broad interest.
Although there are current advances in improved iterations
of established anti-hypertensive medication classes and entire-
ly new medication classes for both established and recently
apparent pathophysiological mechanisms [9], additional poly-
pharmacy may be a less attractive approach in patients with
RHTN. It is estimated that adherence to anti-hypertensive
medications for primary prevention is only ~50% after 2 years
[10]. Dislike of life-long pharmacotherapy and adverse med-
ication effects are some of the reasons thought to underlie this
non-adherence [11], leaving such patients at elevated cardio-
vascular risk. The past decade has seen the introduction of a
suite of interventional approaches for the management of hy-
pertension that are at different stages of clinical development
[12•]. Whilst the majority of these technologies aim to reduce
BP via targeting of the autonomic nervous system [12•], a new
device strategy targeting mechanical properties of the vascular
system has demonstrated significant, sustained and safe blood
pressure lowering in a randomized, controlled trial without
sham treatment. This device addresses the mechanical loss
of arterial compliance, representing a novel treatment strategy
and presenting potential unique clinical value.
Design, Rationale and Development
of the Arteriovenous Anastomotic Coupler
The CE-marked ROX Medical arteriovenous (AV) coupler is
a stent-like device made of nickel/titanium alloy (nitinol) that
exhibits shape memory to self-expand on deployment into a
pre-formed configuration. It is deployed via percutaneous
trans-arterial and -venous access from the external iliac vein
into the adjacent external iliac artery, just above the level of
the femoral head, to form a fixed diameter AV anastomosis
delivering an arterial–venous shunt estimated to be ~0.8–1 L/
min when sized to 4 mm in diameter [13]. The coupler remains
constant in shape and the pressure gradient preserves constant
flow. It was originally developed for the treatment of advanced
chronic obstructive pulmonary disease (COPD) [14••, 15], with
the aim of forming a fixed calibre, central AV anastomosis,
conceived to increase central venous oxygenation. In so doing,
arterial blood saturation is raised despite the venous blood
flowing through pulmonary shunts that do not participate in
gaseous exchange due to the parenchymal destruction in ad-
vanced COPD. Furthermore, the increase in venous return
would cause a commensurate increase in cardiac output, there-
fore further increasing oxygen delivery to tissues [14••].
Initial pilot studies were conducted in two cohorts of pa-
tients with advanced/end-stage COPD. Whilst these initial
studies demonstrated improvements in arterial blood oxygen
content and tissue oxygen delivery, there were heterogeneous
results with respect to functional improvements in exercise
capacity [16, 15]. Although reduction in systemic vascular
resistance [16] and increased cardiac output were demonstrat-
ed [16, 15], the effects on systemic arterial pressure were not
reported. These initial proof-of-concept studies were per-
formed using either end-to-side surgical AV anastomosis
and/or a coupler sized to 5 mm in diameter (i.e., larger than
the current iteration) with an earlier method of procedural
implantation in advanced/end-stage COPD [16, 15]. These
patients have different clinical risks/benefits and certainly
their physiology is appreciably different to patients with
RHTN.Whilst the procedural adverse event rates in these pilot
COPD trials are notable (and includes ipsilateral lower limb
oedema (67 %), venous stenosis (47 %), right heart failure
(27 %) and deep venous thrombosis (27 %)), they cannot
simply be translated to other patient groups with current
device/delivery modifications.
Historical reports show that experimental very large-cali-
bre, non-fixed diameter AV anastomoses in canines caused
significant, sustained reduction in BP, though the maladaptive
responses to such fistulae were not desirable [17, 18]. These
included an increase in cardiac output and heart rate as well as
an increase in total blood volume. In the case of larger or more
proximal fistulae, the resultant hypotension could even be
fatal or eventually cardiac dilatation and high output cardiac
failure would ensue. In modern medical practice, the most
common reason for formation of an iatrogenic AV anastomo-
sis is to provide vascular access (AV fistula or AVF) in patients
with end-stage renal disease (ESRD) for the purpose of
haemodialysis (HD). Closure of AVFs in stable HD patients
post-renal transplantation is associated with elevation in BP
[19] and formation and maturation of upper limb AVFs in pre-
dialysis patients is associated with significant peripheral BP
reduction [20••, 21] and, in addition, reduction in central BP
and aortic pulse wave velocity [20••], both validated measures
of the effects of arterial stiffness [22]. High volume, upper
limbAVF formation for HD has been associated with enlarged
myocardial dimensions and reduction in endothelial function
[23]. However, upper limb AVFs for HD are non-fixed calibre
and dilate over time, have pressure-variable diameters and
blood flow resulting in increased shunt fractions as blood
pressure rises. When fistula flow as a proportion of cardiac
output exceeds 30%, screening for high output failure is often
conducted; however, cardiac failure is seldom reported unless
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the shunt volume is greater than 2 L/min [24]. The ROX
coupler delivers a fixed diameter conduit that can be upsized
only through further balloon dilatation but will not expand
spontaneously, resulting in anastomosis flow rates [13] that
are unlikely to result in cardiac decompensation,
Evidence for Blood Pressure Reduction
in Hypertension
Whilst neither of the two initial published studies in normoten-
sive COPD patients reported changes in systemic arterial BP,
an interesting signal was apparent in a pooled cohort from two
separate clinical trials in COPD patients (clinicialtrials.gov
NCT00832611 and NCT00992680; total n=95). In post hoc
analyses of 24 patients with co-existent (systemic arterial) hy-
pertension (mean resting BP 145/86 mmHg), insertion of the
AV coupler (sized to 4 mm) was associated with 13/18 mmHg
reduction in resting BP at 12 months post-central AV anasto-
mosis formation [25]. More importantly, this effect was con-
sistent with 67 % patients having >10 mmHg systolic blood
pressure (SBP) reduction and 83% patients having >10mmHg
diastolic blood pressure reduction, and negligible BP reduction
in normotensive patients [26, 25]. The adverse event rate was
lower than in the previous studies, with 17 % developing ve-
nous stenosis proximal to the stent insertion point that required
either balloon venoplasty and/or stenting and 17% developing
deep vein thrombosis [25].
Following these observations, a small, prospective study
(unpublished) in eight RHTN patients (mean 4 anti-
hypertensive medications) was conducted using both office
and ambulatory BP measurements to 6 months post-AVanas-
tomosis (4 mm diameter) formation. Office BP (OBP) and
ambulatory BP (ABP) decreased by 17/13 mmHg and by
6/13 mmHg, respectively [27], with some improvements in
echocardiographic measures of diastolic function and left ven-
tricular hypertrophy in a small subset (n=5) [27].
These pilot data spurred the design of a larger, internation-
al, multi-centre, open-label, randomized, controlled trial in
patients with confirmed office and out-of-office RHTN. In
the ROX CONTROL HTN trial [28••], 83 patients were ran-
domized in a 1:1 fashion to receive standard care (medication
continuation) or insertion of the AV coupler plus standard care
until the co-primary endpoint analysis (OBP and ABP) at
6 months, and a modified intention to treat analysis was per-
formed in the 77 patients with complete data at this time-point.
The trial cohort was well balanced between the limbs and
the patients had significant hypertension despite taking >4.6
medications. Baseline OBP was 175/100 mmHg, with out-of-
office RHTN confirmed by ABP (24 h mean 157/93 mmHg).
OBP was significantly reduced by 27/20 mmHg and ABP by
14/14mmHg from baseline in the active treatment group, with
no significant change in the control group [28••]. The
magnitude of BP reduction observed at 6 months post-
intervention was similar to those achieved through first-
generation renal sympathetic denervation (RSD) technology
and second-generation baroreflex activation therapy (BAT)
[29, 30]. In a subset of patients (n=10) who had previously
received RSD, there was an equivalent BP response [28••],
suggesting that inadequate response to one interventional
technology does not preclude response to another, as had pre-
viously been demonstrated with BAT following inadequate
response to RSD [29]. Importantly, the similar reduction in
both SBP and DBP following central AVanastomosis forma-
tion preserves pulse pressure (PP), and therefore, long-term
evaluation of these effects on target organ damage, arterial
stiffness and CVevents is required to demonstrate that main-
tenance of large PP (with lower mean arterial pressure) is
beneficial overall. An initial case report of the effects of cen-
tral AV anastomosis formation on parameters of arterial stiff-
ness 4 months post-AV coupler insertion suggest that reduc-
tion in pulse wave velocity was independent of associated BP-
lowering [31]. In the control group, five admissions for hy-
pertension crisis occurred within the primary analysis 6-
month period, whilst none occurred in the intervention group.
Furthermore, there was medication reduction at 6 months in
25.6% (p=0.03) of patients in the intervention group whilst in
the control group, 29.4 % (p=0.04) of patients increased an-
tihypertensives. This may have led to an underestimate of the
true BP-lowering effect of the coupler as BP analysis was
done independent of medication changes [28••].
Procedural complication rates were common (31 %) and
included an ipsilateral iliac artery dissection, which required
no further intervention (n=1), severe contrast reaction in a
patient with known dye allergy (n=1) and localized time-
limited pain (n=2). Late, device-related events were exclu-
sively related to venous stenosis causing limb oedema in
29 % of patients that were treated successfully by balloon
venoplasty and/or stenting. Venous stenosis is caused by ve-
nous neointimal hyperplasia (VIH) and is a leading cause of
AVF dysfunction in ESRD, with 2-year patency rates of only
75 % [32], and is a leading cause of both morbidity and hos-
pitalization in ESRD patients [33]. Another potential mecha-
nism for ipsilateral limb oedema is venous hypertension from
impaired venous return distal to the anastomosis. Compres-
sion stockings are advised in all patients after device insertion,
and some suggest co-administration of aspirin [25] or diuretics
(current Barts BP Centre practice) to all patients to prevent
these issues, though the efficacy of these approaches are as yet
unknown.
ROX CONTROL HTN did not include a sham-control as
the most recent Food and Drug Administration (FDA) Inves-
tigational Device Exemption (IDE) trial for radio-frequency
(RF) RSDwas designed to do. However, in the case of the AV
coupler technology, a sham-controlled study may not be nec-
essary or feasible. Firstly, upon opening of the anastomosis,
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there is immediate imaging confirmation of anatomical suc-
cess of the procedure and this is confirmed by immediate, on-
table, large reduction in BP [13], unlike RSD where technical
success remains unverified at the time of the procedure. This
immediate blood pressure finding restricts possible influences
of the Hawthorne or placebo effect. Secondly, this therapy
leads to a palpable thrill in the ipsilateral groin that can be felt
by the patient [13].
Proposed Mechanism of Beneficial Haemodynamic
Effects in Hypertension
The mechanisms that regulate BP and can contribute to the
pathophysiology of hypertension and RHTN are complex and
manifold [34]. Two themes that have gained particular atten-
tion over the past two decades are the roles of the autonomic
nervous system and large vessel arterial stiffening in the initi-
ation, maintenance and resistance to pharmacotherapy of hy-
pertension phenotypes.
Tonic elevation of sympathetic tone is widely recognized
as a hallmark of hypertension, particularly in renal- and
obesity-driven forms and in the young [35]. Furthermore,
there is a clear association of increased indirect measures of
sympathetic overactivity in uncontrolled (pharmacologically)
RHTN [36, 37]. These abnormalities drove the development
of two contrasting sympathomodulatory approaches for
RHTN: RSD [38] and BAT [39]. Whilst these technologies
have accrued substantial evidence of BP reduction in most
studies to date and recommendations for use are included in
recent international guidelines [6], sympathomodulation using
RSD has been shown significantly less effective in terms of
BP reduction in the context of isolated systolic hypertension
(ISH) [40, 41], a common finding in middle-aged and older
patients with hypertension [42]. There are multiple mecha-
nisms that may be responsible for BP modulation after crea-
tion of a central AV anastomosis [43••]. Whilst it is predomi-
nantly thought that the BP reduction is related to mechano-
circulatory improvements [28••], there is the possibility that
neurally mediated vasomotor and hormonal alterations also
play a role.
Importance of Arterial Stiffness to Age-Related BP
Elevation
Large, central artery stiffening is due to elastin fatigue, colla-
gen deposition and medial calcific arteriosclerosis [44, 45],
and it precedes incident hypertension in large, prospective
cohorts [46, 47]. Recent computational studies suggest that
large artery stiffening alone is sufficient to explain both age-
related increases in BP and failure of normal regulatory mech-
anisms (primarily renal and baroreflex mediated) to provide
homeostasis [48]. Furthermore, arterial stiffness is implicated
as a leading determinant of resistance to conventional phar-
macotherapy, as most anti-hypertensive medications work at
the level of the muscular arterioles rather than the central,
elastic, large arteries [49••]. Central aortic elastic disorders
inherently raise blood pressure, pulse pressure, pulse wave
velocity all contributing to increases in volume sensitivity
[50] and blood pressure variability [51] (Fig. 1). Loss of aortic
elasticity is a component of ageing and may well explain the
age-related increase in pulse pressure and loss of responsive-
ness to neurohumoral interventions.
Impedance mismatch in the distal aorta, predominantly at
major arterial branching points, leads to pressure-wave reflec-
tion and return of a backward wave that augments systolic BP
on top of the forward, propagation wave that leaves the heart
[52]. This augmentation of central pressures is further in-
creased in the setting of central arterial stiffness, as the lack
of arterial compliance accelerates the velocity of both the for-
ward and backward pressure waves, leading to more overlap
of the distinct pressure waves in systole, leading to greater PP
amplification and thus giving rise to the ISH phenotype [52]
(Fig. 2). Furthermore, there is a contribution to central arterial
stiffness arising from the distending pressure of the pressur-
ized, blood-filled aorta [53], and thus, there is a potential for a
negative feed-forward loop in this regard (Fig. 1).
Loss of arterial compliance necessarily involves loss of the
Windkessel effect within the central arterial vasculature [54].
This loss of pressure dampening (BP cushioning) increases
rate of pressure change within systole in the aorta and predis-
poses to increased systolic BP levels, greater BP variability
and enhanced volume sensitivity of BP levels [55] (Fig. 2).
The resultant magnification of peak systolic BP, PP and BP
variability predisposes to organ damage, such as left ventric-
ular hypertrophy, and increased risk of CVevents [56].
Fig. 1 Feed-forward loop involving blood pressure parameters,
circulatory damage and arterial stiffness
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Central AVAnastomosis: Targeting Mechano-circulatory
Aspects
There are several mechanisms by which creation of a central,
fixed calibre AV anastomosis will target abnormal mechano-
circulatory aspects of vascular physiology in hypertension that
are likely to be additive and work in a beneficial feed-forward
loops.
The addition of a low-resistance, high-compliance venous
segment in parallel to the systemic arterial circulation will
reduce overall systemic vascular resistance (SVR) (as has
been demonstrated with the formation of a central AVanasto-
mosis in the original pilot studies [16]), similar to Ohm’s law
of electrical resistance.With a more proximal anastomosis, the
reduction in SVR will be relatively greater than for distal
circulatory AV conduits (such as upper limb AVFs) in relation
to the contribution of vessel length to flow through a fixed
diameter vessel/tube (Poiseuille’s Law). With increased ve-
nous return, there is activation of the Starling mechanism to
increase cardiac output [16, 15, 20••, 21], equivalent to the
anastomosis flow rate (~1 L/min); however, if the increase in
cardiac output is not commensurate with the reduction in SVR
caused by the addition of the parallel, low-resistance circuit,
then mean arterial pressure will drop as is the case with HD
AVF formation as previously discussed [20••]. Cardiac
afterload is thereby reduced through a variety of mechanisms,
including reduction of effective arterial volume and arterial
stress, slowing of reflected pressure waves and preventing
their systolic stacking. Importantly, reduction in effective ar-
terial volume achieved through a central AVanastomosis does
not come at the expense of reduction in whole-body volume
affecting the intracellular, interstitial and venous capacitance
compartments as typified by use of diuretics which are known
to result in a concomitant increase in sympathetic outflow and
may be responsible for attenuation of anti-hypertensive effect
[57, 58].
Perhaps most importantly, merely reducing effective arte-
rial volume and cardiac afterload with a central AVanastomo-
sis will alter the strain–stress intercept that reflects the non-
linear volume/pressure dependency that determines arterial
compliance (the reciprocal of arterial stiffness). This relation-
ship is pathophysiologically shifted leftwards in hypertension
Fig. 2 Modifying effects of arterial ageing/stiffness on the arterial
pressure waveform. Incident (i) pressure waves leave the heart during
systole and are accommodated by the Windkessel effect in young
elastic arteries. Reflected (r) waves from arterial branching points arrive
late in relation to the i wave and do not contribute to pressure
amplification. In aged, stiff arteries, there is a loss of BP cushioning and
early reflection of r waves, leading to increased systolic and pulse
pressures (BP blood pressure)
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related to arterial stiffening (Fig. 3). This change will allow for
some improvement in BP cushioning and return of a
Windkessel-like effect, further reducing pulse pressure ampli-
fication due to a delayed return of the reflected wave and
reduced pressure stacking. Reduction of distending BP in
the aorta will also further improve arterial compliance, and
therefore, there is a possibility of a feed-forward loop occur-
ring between reduced SVR, improved compliance, and re-
duced distending BP and the long-term possibilities of bene-
ficial aortic remodeling (Fig. 3).
Central AVAnastomosis: Neurohumoral
and Sympathomodulatory Aspects
In addition to several mechano-circulatory aspects that may
contribute to mean BP and BP variability improvements
discussed above, there may well be anticipated benefits from
neurohumoral and sympathomodulatory aspects. Increased
flow to the cardio-pulmonary circuit will stimulate release of
atrial natriuretic peptide, which may augment BP reduction as
it is a potent vasorelaxant peptide that additionally has tubular
effects in the glomerulus to reduce sodium reabsorption [59].
Furthermore, increased cardiac output resulting in stimulation
of right atrial baroreceptors (via the Bainbridge reflex) and
possibly cardiac vagal mechanoreceptors (via increased para-
sympathetic tone) may cause a beneficial sympathomodulatory
effect on natriuresis and vasomotor tone [60].
The combination of increased cardiac output [13] and arte-
rial blood oxygen content [16] will improve delivery of
oxygen to various tissue beds, with possible beneficial effects,
mediated in part by inhibition of peripheral carotid chemore-
ceptor activity, which augments sympathoexcitation and is
reduced with hyperoxia [61]. This arises by improving renal
oxygenation and thus downregulating afferent sympathetic
signalling from ischaemia-sensitive renal chemoreceptors
[62] and by reducing hypoxia-dependent pulmonary arterial
vasoconstriction that would facilitate further improvements in
systemic oxygenation.
Future Directions
In common with similar early-phase investigations of inter-
ventional strategies for hypertension, ROX CONTROL HTN
was designed to evaluate safety and efficacy of a primary
endpoint and not designed to evaluate reductions in target
organ damage or hard CV endpoints, and therefore, longer-
term follow-up in global registries and investigator-led studies
will be necessary to demonstrate an equivalent evidence base
to guideline-based pharmacotherapy [2]. In addition, reporting
on late complications is pending further follow-up on the re-
ported cohort. A FDA, US-based IDE trial is in development
and will help better define the optimal target population(s) and
expected benefit and risks. A global registry (RH03) has
started recruitment with the aim of entering 100 RHTN pa-
tients with ongoing follow-up to determine long-term efficacy
and safety (clinicaltrials.gov: NCT01885390) and may allow
for the inclusion of other hypertension phenotypes, such as
Fig. 3 Age-related changes in the
stress–strain relationship may be
modified by central arteriovenous
anastomosis. Age-related arterial
stiffness moves the stress–strain
relationship in the major elastic
arteries to the left, reducing
distensibility for a given BP.
Effective reduction in arterial
volume shifts the operating curve
of the stress–strain relationship
downwards, resulting in a
pseudonormalisation of
relationship. Further arterial
remodeling may allow the stress–
strain relationship to drift back
towards the right towards
normality allowing greater
compliance for a given BP (BP
blood pressure)
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multi-drug intolerant patients, for whom there are extremely
limited treatment options [63]. Additional, serial testing will
be performed at some sites to include detailed cardiac struc-
tural evaluation, to determine whether non-fixed calibre AVF
formation in non-ESRD patients is associated with previously
observed maladaptive changes [23]. Non-invasive autonomic
testing with simultaneous beat-by-beat haemodynamic assess-
ment could in addition determine whether the observed BP-
lowering effects are purely mechano-circulatory or involve
sympathomodulation as well.
Other avenues that are being explored in nascent clinical
trials include evaluating the effects of the coupler in paroxys-
mal atrial fibrillation (AF), as an adjunct to AF ablation
(clinicaltrials.gov: NCT02243891) and in neurally mediated
syncope (clinicaltrials.gov: NCT02388087) where it is postu-
lated that increases in cardiac pre-load will reduce symptoms.
Due to the expected reduction in cardiac afterload related to
reduction in SVR and improvements in arterial compliance, it
has been suggested that improvements in cardiac mechanics
and reductions in myocardial oxygen consumption may be
apparent [13], which would provide the possibility of an ad-
ditional research stream in refractory angina, though to date,
no pre-clinical or clinical data has been presented to demon-
strate these effects.
In common with more established interventional technolo-
gies in the field of hypertension, such as RSD and BAT, iter-
ation of the device and deployment technique may be possible
to improve efficacy and enhance safety. One possibility is for
graded sizing of the AVanastomosis, so that patients first have
a smaller calibre anastomosis formed (e.g., 2–3 mm diameter)
and that if BP reduction related to this effect is not sufficient to
control BP to guideline-driven targets, then the anastomosis
could be further dilated to achieve the necessary haemody-
namic effect. Furthermore, procedural modification is desir-
able to minimize venous trauma and modulation of artery-to-
vein flow to avoid neo-intimal hyperplasia in order to reduce
the prevalence of venous stenosis.
Conclusions
Formation of a central AVanastomosis via a proprietary anas-
tomotic coupler device has joined the burgeoning suite of
interventional strategies for the reduction of BP in
(pharmacologically) RHTN. Although its beneficial effects
are likely to be related to mechano-circulatory improvement
in SVR and arterial compliance, there is the possibility that it
is sympathomodulatory in addition. Clinical trial data to date
is encouraging, but both regulatory authorities and interna-
tional guideline-writing societies will require further safety
and hard CV end-point data before it becomes an established
weapon in the anti-hypertensive armamentarium.
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